摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

| 1046790-58-2

中文名称
——
中文别名
——
英文名称
——
英文别名
——
化学式
CAS
1046790-58-2
化学式
C21H25F3N6
mdl
——
分子量
418.465
InChiKey
FAHQRMHXJUXBBI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    30.0
  • 可旋转键数:
    5.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    87.2
  • 氢给体数:
    3.0
  • 氢受体数:
    5.0

反应信息

  • 作为反应物:
    描述:
    三氟乙酸 反应 2.0h, 以28 mg的产率得到2-(trifluoromethyl)-4-(3-{4-[2-(trifluoromethyl)-1H-benzo[d]imidazol-4-yl]piperazin-1-yl}propyl)-1H-benzo[d]imidazole bis(trifluoroacetate)
    参考文献:
    名称:
    2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor
    摘要:
    Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and antagonists. Recently, small molecule GnRH antagonists have emerged as potentially new treatments. This article describes the discovery of 2-phenyl-4-piperazinylbenzimidazoles as small molecule GnRH antagonists with nanomolar potency in in vitro binding and functional assays, excellent bioavailability (rat % F > 70) and demonstrated oral activity in a rat model having shown significant serum leuteinizing hormone (LH) suppression. (c) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2008.05.024
  • 作为产物:
    描述:
    2-nitro-6-(3-{4-[2-(trifluoromethyl)-1H-benzo[d]imidazol-4-yl]piperazin-1-yl}propyl)aniline 在 tin(ll) chloride 作用下, 以 N-甲基吡咯烷酮 为溶剂, 反应 5.5h, 生成
    参考文献:
    名称:
    2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor
    摘要:
    Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and antagonists. Recently, small molecule GnRH antagonists have emerged as potentially new treatments. This article describes the discovery of 2-phenyl-4-piperazinylbenzimidazoles as small molecule GnRH antagonists with nanomolar potency in in vitro binding and functional assays, excellent bioavailability (rat % F > 70) and demonstrated oral activity in a rat model having shown significant serum leuteinizing hormone (LH) suppression. (c) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2008.05.024
点击查看最新优质反应信息